ArticleBMC medical genomics2026
TMEM201 regulates tumor malignancy and immune microenvironment in lower-grade glioma.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTMEM201, a nuclear membrane protein, is thought to play an important role in tumor progression, but its involvement in lower-grade glioma (LGG) remains unclear. This study aims to investigate the impact of TMEM201 expression on the prognosis, clinical characteristics, and biological behaviors of LGG.
methodsRNA expression data from the TCGA, CGGA, and GEO databases were analyzed to explore the correlation between TMEM201 expression and clinical features of LGG. In vitro and in vivo experiments were conducted to assess the effects of TMEM201 knockdown on cell proliferation, migration, and tumorigenic potential. DNA methylation sites associated with TMEM201 were analyzed, and KEGG pathway enrichment was performed to identify the molecular mechanisms underlying TMEM201’s role in LGG.
resultsThe analysis showed that high TMEM201 expression was associated with poor prognosis, higher WHO grade, and tumor recurrence in LGG patients. Survival analysis confirmed that elevated TMEM201 levels correlated with shorter survival. Knockdown of TMEM201 in SHG44 cells led to significant inhibition of cell proliferation, migration, and tumor formation in vivo. DNA methylation analysis identified key sites regulating TMEM201 expression, and KEGG analysis revealed pathways such as HIF-1, VEGF, and Notch that contribute to tumor progression.
conclusionTMEM201 acts as a potential oncogene in LGG by influencing key cellular signaling pathways and tumor behaviors. It is an independent risk factor for poor prognosis and may serve as a promising biomarker for diagnosis and personalized treatment. This study provides valuable insights into the molecular mechanisms of LGG progression and highlights TMEM201 as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.